Clinical Trials Browser

Phase 1/2 × Neoplasms × Pemetrexed × Clear all

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

NCT05407675 2025-10-03

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

68 enrolled 27 charts

Tumor-Agnostic

Neoplasms

NCT04717375 2025-08-07

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Phase 1/2 Terminated

125 enrolled

Tumor-Agnostic

Neoplasms

NCT05180799 2025-06-15

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Phase 1/2 Active not recruiting

320 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms

NCT03267316 2024-08-22

CANFOUR

Phase 1/2 Completed

167 enrolled

BreastGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02439450 2023-09-21

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Phase 1/2 Completed

121 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01397305 2020-09-09

An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

Phase 1/2 Completed

24 enrolled

Gastrointestinal

Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Site, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

Clinical Trials

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

CANFOUR

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer